Retatrutide Therapy: Complete Guide
Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. In the Phase 2 TRIUMPH trial, participants on the highest dose lost an average of 24.2% of body weight over 48 weeks, with some Phase 3 cohorts reporting losses above 28%. Expected to file an NDA with the FDA in Q4 2026, retatrutide is widely anticipated to become the next major advance beyond tirzepatide for obesity and metabolic disease.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is Retatrutide?
What Is Retatrutide?
Retatrutide (development code LY3437943) is Eli Lilly's investigational triple-agonist peptide for obesity and type 2 diabetes. It is the first therapy in development to activate all three incretin-family receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Each receptor contributes a distinct metabolic lever — GLP-1 suppresses appetite, GIP enhances insulin signaling and fat metabolism, and glucagon increases energy expenditure. Combined, these pathways have produced the largest weight-loss results ever reported in a Phase 2 obesity trial.
Why Retatrutide Matters
Tirzepatide (Mounjaro/Zepbound) established the dual GIP/GLP-1 mechanism in 2022 with ~22.5% average weight loss in SURMOUNT-1. Retatrutide raises that ceiling further by adding glucagon receptor activation, which increases resting energy expenditure and enhances lipolysis. In the 2023 New England Journal of Medicine Phase 2 obesity trial, participants at the 12 mg dose had 24.2% mean body-weight reduction over 48 weeks. Lilly later reported Phase 3 TRIUMPH-1 efficacy-estimand weight loss of 28.3% at 80 weeks with 12 mg, and TRIUMPH-4 efficacy-estimand weight loss of 28.7% at 68 weeks with 12 mg in adults with obesity or overweight and knee osteoarthritis.
Regulatory Timeline
Eli Lilly is conducting the TRIUMPH Phase 3 program across obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, cardiovascular and renal outcomes, MASH (metabolic-associated steatohepatitis), and other obesity-related indications. Lilly says it plans to submit a BLA in Q1 2027 for U.S. approval. Retatrutide is not FDA-approved, not commercially available, and legitimate access is currently limited to clinical trials. Research-chemical vendors selling "retatrutide" are not providing FDA-regulated product, and patient safety cannot be assured through those channels.
How Retatrutide Works
Triple-Receptor Agonism
Retatrutide is a 39-amino-acid peptide engineered to activate three distinct receptors with calibrated potency. The balance between the three activities is a critical design feature — activation must be strong enough to drive therapeutic effects but balanced enough to avoid hyperglycemia from the glucagon arm.
GLP-1 Receptor Activation
As with semaglutide and tirzepatide, GLP-1 receptor activation in the hypothalamus reduces appetite and increases satiety. In the pancreas, it drives glucose-dependent insulin secretion and suppresses glucagon in the post-meal state. GLP-1 activity also slows gastric emptying, extending satiety after meals.
GIP Receptor Activation
GIP activation amplifies insulin release, improves beta-cell function, and — counterintuitively — enhances adipose tissue insulin sensitivity, which appears to reduce inflammation in fat depots. GIP activity is thought to contribute to the better GI tolerability of tirzepatide relative to semaglutide, and this pattern appears to extend to retatrutide.
Glucagon Receptor Activation
This is the novel arm. Glucagon is typically thought of as the counter-regulatory hormone that raises blood sugar, but its receptor activity also increases resting energy expenditure, enhances hepatic fat oxidation, and promotes lipolysis in adipose tissue. By pairing glucagon activity with strong GLP-1 and GIP signaling, retatrutide achieves weight loss through both reduced intake (appetite suppression) and increased output (energy expenditure) — a mechanism not available with single or dual agonists.
Pharmacokinetics
Retatrutide has a half-life supporting once-weekly subcutaneous dosing, similar to tirzepatide and semaglutide. A fatty acid side chain extends circulation by binding albumin.
Benefits & Uses
Clinical Benefits Reported in Trials
- Weight loss: In the Phase 2 obesity trial, 17.1% (combined 4 mg), 22.8% (combined 8 mg), and 24.2% (12 mg) mean body-weight reduction over 48 weeks. In Phase 3, Lilly reported TRIUMPH-1 efficacy-estimand weight loss of 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) at 80 weeks, and TRIUMPH-4 efficacy-estimand weight loss of 28.7% with 12 mg at 68 weeks in adults with obesity or overweight and knee osteoarthritis.
- Waist circumference: Reductions of 15–20 cm in high-dose arms, reflecting substantial visceral adipose loss.
- Liver fat: Dramatic reductions in hepatic steatosis — Phase 2 MASH data showed ≥85% relative liver fat reduction in high-dose participants.
- Glycemic control: HbA1c reductions of 1.6–2.0 percentage points in type 2 diabetes participants.
- Blood pressure: Systolic BP reductions of 7–11 mmHg across dose ranges.
- Triglycerides and lipids: Improvements in triglycerides, LDL, and HDL comparable to or exceeding tirzepatide.
- Apnea-hypopnea index: Trials underway in obstructive sleep apnea; preliminary data favorable.
Mechanism-Driven Advantages
The glucagon component drives energy expenditure, meaning weight loss is not purely from reduced caloric intake. This may translate to better preservation of metabolic rate during and after weight loss — a potential advantage over caloric restriction and single-receptor agonists where metabolic adaptation can blunt long-term results.
Clinical Evidence & Research
Phase 2 Obesity Trial
Jastreboff et al., New England Journal of Medicine, 2023 — 338 participants with obesity randomized to retatrutide at 1, 4, 8, or 12 mg weekly vs placebo for 48 weeks. Least-squares mean body weight change at 48 weeks: −24.2% at 12 mg, −22.8% in the combined 8 mg group, −17.1% in the combined 4 mg group, vs −2.1% placebo. At least 15% weight loss occurred in 75% of participants in the 8 mg group and 83% in the 12 mg group.
Phase 2 Type 2 Diabetes Trial
Rosenstock et al., The Lancet, 2023 — HbA1c reductions of 1.6–2.0% with weight loss of 8.9–16.9% across retatrutide doses over 36 weeks. Comparable or superior to dulaglutide and placebo arms.
Phase 2 MASH (Liver Disease)
Sanyal et al., 2024 — Reported relative reductions in liver fat of 82.4% at the 8 mg dose and 85.6% at 12 mg over 48 weeks in participants with hepatic steatosis, alongside substantial weight loss.
TRIUMPH Phase 3 Program
The initial global registrational TRIUMPH program includes TRIUMPH-1 for obesity or overweight without diabetes, TRIUMPH-2 for obesity or overweight with type 2 diabetes, TRIUMPH-3 for severe obesity with established cardiovascular disease, and TRIUMPH-4 for obesity or overweight with knee osteoarthritis. Lilly says these data support planned U.S. BLA submission in Q1 2027.
Side Effects & Safety
Common Side Effects
- Nausea — most common, particularly during dose escalation. Typically improves after 2–4 weeks at a given dose.
- Vomiting — more common at high doses; slower titration reduces incidence.
- Diarrhea — dose-dependent.
- Constipation — frequent, especially at higher doses.
- Decreased appetite — expected mechanism.
- Injection-site reactions — mild redness or irritation.
Class-Level Concerns
Retatrutide carries the full incretin-family safety profile:
- Pancreatitis risk (rare but requires monitoring).
- Gallbladder disease, particularly with rapid weight loss.
- Heart rate increase of 3–8 beats per minute reported in trials.
- Thyroid C-cell tumor risk (boxed concern with GLP-1 class; animal-only signal).
Glucagon-Specific Considerations
The glucagon arm can raise blood glucose in susceptible patients. In clinical trials, dose titration is designed to balance glucagon activity against GLP-1/GIP activity. Patients with poorly controlled diabetes, severe hepatic impairment, or cardiovascular instability require careful evaluation and are typically excluded from current protocols.
Long-Term Safety
Follow-up beyond 48–72 weeks remains limited. The Phase 3 program is designed to generate multi-year safety data, particularly around cardiovascular outcomes and any metabolic rebound after discontinuation.
Dosing & Administration
Clinical Trial Dosing
Retatrutide is administered by weekly subcutaneous injection. Trial protocols use a careful titration approach because the therapeutic doses significantly exceed those used for semaglutide or tirzepatide:
- Weeks 1–4: 2 mg weekly
- Weeks 5–8: 4 mg weekly
- Weeks 9–12: 6 mg weekly
- Weeks 13–16: 8 mg weekly
- Weeks 17+: 8 mg or 12 mg maintenance, depending on tolerability and weight-loss goals
Administration
Subcutaneous injection into the abdomen, thigh, or upper arm, with site rotation to minimize local irritation. The exact commercial dosing format (pre-filled pen vs multi-dose cartridge) will be set at FDA approval.
Current Access
Retatrutide is not yet FDA-approved and is not available by prescription. Legitimate access is limited to participation in active clinical trials. Consult clinicaltrials.gov for current enrollment opportunities and speak with a qualified provider about whether retatrutide trial enrollment may be appropriate for your situation. Research-chemical vendors selling "retatrutide" online are not providing an FDA-regulated product, and safety, potency, and purity cannot be guaranteed.
Find Retatrutide Providers Near You
Browse 2 listed providers offering Retatrutide therapy in our directory. Compare clinics by location, telehealth availability and insurance acceptance.
Browse ProvidersRetatrutide FAQ
Eli Lilly says it plans to submit a BLA to FDA in Q1 2027 based on TRIUMPH Phase 3 results. Any FDA approval would come only after review. Retatrutide is not FDA-approved and is not legitimately available by prescription today.
In the 2023 NEJM Phase 2 obesity trial, participants on 12 mg weekly had 24.2% mean body-weight reduction over 48 weeks. In Phase 3, Lilly reported TRIUMPH-1 12 mg at 28.3% over 80 weeks using the efficacy estimand, and TRIUMPH-4 12 mg at 28.7% over 68 weeks using the efficacy estimand in adults with obesity or overweight and knee osteoarthritis.
In cross-trial comparison, retatrutide produced 24.2% mean body-weight reduction at 12 mg over 48 weeks in the Phase 2 obesity trial, while tirzepatide produced ~22.5% at 15 mg over 72 weeks in SURMOUNT-1. However, retatrutide is not yet approved, and head-to-head randomized data are limited. Tirzepatide is the current best-in-class approved therapy; retatrutide is expected to raise the ceiling if approved.
The primary side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. Modest heart-rate increases (3–8 bpm) have been observed. The glucagon component can affect blood sugar in susceptible patients. Long-term safety is still being established through Phase 3.
No. Retatrutide is not FDA-approved and therefore cannot be legally compounded for patient use in the United States. Online "research peptide" vendors selling retatrutide are not providing FDA-regulated product, and patient safety, dose accuracy, and purity cannot be assured through those channels.
Semaglutide activates GLP-1 alone. Tirzepatide activates GLP-1 + GIP. Retatrutide adds a third lever — glucagon receptor activation — which increases resting energy expenditure and enhances fat oxidation. This triple mechanism produces greater weight loss than either single- or dual-agonist approaches.
What Retatrutide is used for
Each of these reviews the evidence for that goal, including where it is weaker than the marketing suggests.
Stay Updated
Get notified when new peptide therapy providers join in your area.
Retatrutide Deep-Dive Questions
In-depth answers to the most common questions about Retatrutide, grouped by topic.
Legality & Regulation
Comparisons
Dosing & Protocol
Side Effects & Safety
Related Peptides
Sources
Primary literature, regulatory filings, and prescribing information behind this guide. External links open in a new tab.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.